CynergisTek Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CynergisTek in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CynergisTek stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTEK, but not buy additional shares or sell existing shares.
View analyst ratings for CynergisTek or view top-rated stocks.

Wall Street analysts have given CynergisTek a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CynergisTek wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

CynergisTek saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 52,200 shares, an increase of 108.0% from the January 28th total of 25,100 shares. Based on an average daily volume of 340,900 shares, the short-interest ratio is currently 0.2 days. Approximately 0.6% of the shares of the company are short sold.
View CynergisTek's Short Interest.

CynergisTek is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for CynergisTek.

CynergisTek, Inc. (NYSEAMERICAN:CTEK) announced its quarterly earnings results on Thursday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.06. The company earned $4.50 million during the quarter. CynergisTek had a negative net margin of 29.50% and a negative trailing twelve-month return on equity of 18.86%.
View CynergisTek's earnings history.

CynergisTek's stock was trading at $2.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CTEK stock has decreased by 17.0% and is now trading at $2.10.
View which stocks have been most impacted by COVID-19.

1 analysts have issued 12-month price objectives for CynergisTek's stock. Their forecasts range from $4.00 to $4.00. On average, they expect CynergisTek's stock price to reach $4.00 in the next year. This suggests a possible upside of 90.5% from the stock's current price.
View analysts' price targets for CynergisTek or view top-rated stocks among Wall Street analysts.

Some companies that are related to CynergisTek include Logiq (WEYL), China Customer Relations Centers (CCRC), Iota Communications (IOTC), TuanChe (TC), Protagenic Therapeutics (PTIX), OmniComm Systems (OMCM), Generation Hemp (GENH), MJ (MJNE), ALJ Regional (ALJJ), BSQUARE (BSQR), Research Solutions (RSSS), Solbright Group (SBRT), The OLB Group (OLB), PPJ Healthcare Enterprises (PPJE) and Cypress Environmental Partners (CELP).
View all of CTEK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CynergisTek investors own include SeaChange International (SEAC), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Invesco (IVZ), VBI Vaccines (VBIV), Actinium Pharmaceuticals (ATNM), Centennial Resource Development (CDEV), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO) and Matinas BioPharma (MTNB).

CynergisTek trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CTEK."

CynergisTek's stock is owned by a number of retail and institutional investors. Top institutional investors include Horton Capital Management LLC (6.67%), Essex Investment Management Co. LLC (1.64%), Renaissance Technologies LLC (1.35%) and Greenhaven Road Investment Management L.P. (0.29%). Company insiders that own CynergisTek stock include Dana Davis Sellers, John D Abouchar, Judith Finger Krandel, Mark D Roberson, Paul Thomas Anthony, Robert Mccashin and William Caleb Barlow.
View institutional ownership trends for CynergisTek.

CTEK stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Horton Capital Management LLC, Renaissance Technologies LLC, and Greenhaven Road Investment Management L.P.. Company insiders that have bought CynergisTek stock in the last two years include Dana Davis Sellers, John D Abouchar, Judith Finger Krandel, Mark D Roberson, Paul Thomas Anthony, Robert Mccashin, and William Caleb Barlow.
View insider buying and selling activity for CynergisTek or or view top insider-buying stocks.

Shares of CTEK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTEK stock can currently be purchased for approximately $2.10.

CynergisTek has a market capitalization of $22.37 million and generates $21.36 million in revenue each year.

CynergisTek employs 137 workers across the globe.

The official website for CynergisTek is www.cynergistek.com.

CynergisTek is headquartered at 11940 JOLLYVILLE ROAD SUITE 300N, AUSTIN TX, 78759.

CynergisTek's mailing address is 11940 JOLLYVILLE ROAD SUITE 300N, AUSTIN TX, 78759. The company can be reached via phone at 949-614-0700 or via email at [email protected]